Leading biotech firm Intas Biopharmaceuticals will invest Rs 160 crore to set up a new drug manufacturing facility at Sanand near Ahmedabad.
The facility, dedicated for Monoclonal Antibodies (MAbs), will undertake large-scale manufacturing of the recombinant product with a capacity of 5000L in phases.
Intas has signed a Memorandum of Understanding (MoU) with the government of Gujarat for availing special incentives for the project.
Dr. Dhananjay Patankar, Chief Technical Officer, Intas said: “The commercial production at the proposed MAbs facility is likely to commence by 2011. We have initiated the necessary technical studies for the project."
